Could a simple sugar ease Crohn's? new trial aims to find out
NCT ID NCT07225998
First seen Jun 24, 2026 · Last updated Sep 11, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether an oral supplement called N-acetylglucosamine (GlcNAc) can safely help control Crohn's disease in the ileum or ileocolon. Forty adults with stable Crohn's will receive either GlcNAc or a placebo for 6 weeks, then switch after a washout period. The study focuses on safety and symptom changes, and includes people with and without a specific genetic variant linked to the disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- N-acetylglucosamine (GlcNAc)
- What this could lead to
- If it works, this could point toward a new treatment option for Crohn's disease, especially for patients with a specific genetic mutation.
- What could go wrong
- This is a small, early-phase proof-of-concept study. It may not show clear benefit, and results may not apply to all Crohn's patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age 18 and 80 years of age 2. Diagnosis of CD involving ileum (L1) or ileocolonic disease (L3) of any disease behavior 3. On stable dosing of any CD therapy for \>/= 8 weeks (inclusive of biologics, small molecules, immunomodulators) 4. CDAI \<450 5. Willing to undergo genetic testing for ZIP8 genotype 6. No steroids within the past 4 weeks 7. No antibiotics within the past 2 weeks 8. Willing to provide informed consent 9. Willing to participate in all at-home and clinic-based follow-up 10. Willing to provide most recent endoscopy and imaging results; when possible, access to prior pathology specimens 11. Willing to use all forms of "highly effective" contraception throughout the study period and for 30 days after the last dose of study drug (all subjects of child-bearing potential) Exclusion criteria 1. Have taken GlcNAc or glucosamine in the previous 3 months 2. Allergy to shellfish 3. Severely-active CD defined as CDAI \>450 AND/OR 4. Simple Endoscopic Score for Crohn's Disease (SES-CD) score \>/= 16 (or \>/= 8 for isolated ileitis) on colonoscopy within 8 weeks of screening, if available 5. Steroids within the past 4 weeks 6. Antibiotics within the past 2 weeks 7. Stricture with high-grade obstruction, significant fistulizing disease, presence of intra-abdominal or perianal abscess, perforation, or fulminant colitis requiring imminent surgical management 8. Surgery within 12 weeks 9. Recent initiation or escalation of immunosuppressive therapy (\<8 weeks) 10. Any clinically significant abnormalities on routine clinical labs, including unexplained white blood cells (WBC) \>16,000, hemoglobin \<7, AST/ALT \>2x ULN, alkaline phosphatase \>2x ULN, eGFR \<60, ferritin \<30 ng/ml2 11. History of type 1 diabetes, inadequately controlled type 2 diabetes (HbA1c\>6.5%), type 2 diabetes on insulin 12. History of peripheral vascular disease, coronary artery disease, stroke, transient ischemic attack 13. History of cancer 14. History of organ transplant 15. History of bleeding disorder 16. History of chronic respiratory disorder, including asthma 17. History of chronic renal failure 18. History of chronic liver disease, including primary sclerosing cholangitis 19. History of seizure disorder 20. Pregnant, less than 6 months postpartum, breastfeeding, or attempting to conceive
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Crohns disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Johns Hopkins University School of Medicine
Baltimore, Maryland, 21205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple hospital checklist could flag hidden malnutrition in kids with IBD
- Green gut check: can ultrasound slash the carbon cost of IBD testing?
- Real-World surgery study aims to improve fistula care
- New Dye-Free colonoscopy could make cancer screening easier for IBD patients
- Hidden mineral shortage: new study targets magnesium in gut patients
- Real-World study tracks how IBD patients choose between IV and injectable vedolizumab